Appointment of Joint Broker

RNS Number : 4121Z
IXICO plc
06 February 2014
 



6 February 2014

 

 

IXICO plc

Appointment of Joint Broker

 

IXICO plc (Ticker: IXI) ("IXICO" or the "Company"), the brain health company, today announces the appointment of Daniel Stewart & Company as its joint broker with immediate effect.

 

 

Enquiries

 

IXICO plc

+44 207 691 2064

Derek Hill, CEO

Charles Spicer, Director

 

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+44 207 418 8900

James Steel

Clare Terlouw

 

Daniel Stewart & Company (Joint Broker)

+44 207 776 6550

Mark Treharne

David Hart

 

FTI Consulting Limited (U.K. Investor and Media Relations)

+44 207 831 3113

John Dineen

Simon Conway

 

About IXICO

IXICO, the brain health company, was founded in 2004 with a mission to translate image acquisition, management and analysis technology and know-how, which the founders had developed together, into commercial products targeting the expanding area of imaging to inform decision-making during drug development. This has resulted in commercially successful products being launched in the clinical trials (Phase 0-III) and experimental medicine markets and more recently launched into the wider clinical diagnostic market. Since incorporation, IXICO has been awarded contracts by eight of the top 15 global pharmaceutical companies as well as leading biotechnology companies. In October 2013, IXICO plc was admitted to trading on AIM. More information is available on www.ixico.com

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
APPBIGDDDXGBGSU

Companies

Ixico (IXI)
UK 100

Latest directors dealings